Table 1. Assayed soluble plasma markers

Biomarker	Baseline	On-panobinostat *Early*	*P*	On-panobinostat *Late*	*P*	Post-panobinostat	*P*
hs-CRP, mg/L	2.3 (0.9-3.6)	0.87 (0.5-2.1)	.073	0.65 (0.4-2.4)	.010*	0.88 (0.45-2.8)	.010*
IL-6, pg/mL	1.7 (1.4-2.8)	2.3 (1.4-5.0)	.36	1.4 (1.0-2.0)	.33	1.4 (0.5-1.7)	.011*
sCD40L, ng/mL	14.8 (8.6-16.0)	ND	ND	6.4 (0.6-10.8)	.0034*	2.0 (1.0-8.8)	<.0001*
MMP-9, ng/mL	26.8 (19.0-37.5)	15.0 (12.8-20.8)	<.0001*	18.4 (14.6-21.1)	<.0001*	23.1 (17.3-27.6)	.018*
E-selectin, ng/mL	35.7 (20.1-41.8)	31.6 (18.4-39.9)	<.0001*	28.3 (19.0-35.7)	.0003*	30.4 (21.6-37.2)	.12
P-selectin, ng/mL	41.3 (33.8-55.2)	34.4 (32.2-41.6)	.0015*	43.6 (40.5-52.8)	.15	57.4 (43.8-72.1)	.0015*
VCAM-1, ng/mL	533.8 (475.3-679.3)	579.5 (490.2-629.5)	.60	544.5 (496.4-661.2)	.30	471.8 (411.1-706.8)	.073
ICAM-1, ng/mL	142.4 (121.8-206.7)	145.5 (114.1-218.9)	.45	150.3 (115.3-211.5)	.68	143.2 (122.2-194)	.14
D-dimer, µg/L	124.0 (99.2-205.0)	114.3 (108.6-199.2)	.60	127.4 (92.2-156.9)	.36	124.7 (86.3-160.0)	.064
sCD14, µg/mL	1.5 (1.3-1.9)	2.0 (1.7-2.3)	.002*	1.5 (1.1-2.0)	.40	1.4 (1.2-1.7)	.12
PAI-1, ng/mL	1.5 (1.2-2.6)	1.6 (1.3-2.7)	.30	2.2 (1.6-3.4)	.035*	1.8 (1.3-3.0)	.12
sTF, pg/mL	38.0 (34.9-40.2)	37.5 (33.0-41.5)	.89	36.6 (32.4-41-4)	.72	35.3 (33.1-40.9)	.76

Baseline is a mean of 2 measurements seperated by 4 weeks. On-panobinostat is analyzed in the first and third treatment cycle. Post-panobinostat is analyzed 4 weeks after completing treatment.
Values are shown as median (IQR).
hs-CRP indicates high sensitivity C-reactive protein; IL-6, Interleukin 6; sCD40L, soluble CD40 ligand; MMP-9, Matrix metalloproteinase 9; VCAM-1, Vascular cell adhesion molecule 1; ICAM-1, Intercellular adhesion molecule 1; sCD14, soluble CD14; PAI-1, Plasminogen activator inhibitor 1;and sTF, soluble tissue factor.
* Asterix after p-value indicate their significance
ND, Not determined.



Figure S1: Gating strategy in flow samples. Thawed PBMCs from 10 HIV infected individuals were used to determine monocyte phenotype changes by flow cytometry. (A) Only singlets and live cells were included in the analysis. Monocytes were identified by lack of CD3, CD20 and CD56 expression, and by size and granularity. (B) In addition to the MFI level of CD14 and CD16, the three subsets were identified using an isotype control. (C) The expression level of tissue factor was determined using an isotype control.